COMPANY

Amplo Biotechnology

Keywords: AAV Congenital Myasthenia Syndrome AMP-101

Location: Pompano Beach, FL · source · Oct 4, 2021

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.36M (STTR Phase II 5R42NS127713-04, continuation, notice May 12, 2026). NIH RePORTER 5R42NS127713-04 (May 12, 2026)
Evidence (1 event)
- May 12, 2026 · NIH RePORTER 5R42NS127713-04
  Organization: AMPLO BIOTECHNOLOGY, INC.; City/State: TOWSON, MD; Project number: 5R42NS127713-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1357367; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Targeted ColQ gene therapy for Congenital Myasthenic Syndromes; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Oct 1, 2026 Trial start Phase 1: Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome source ↗
May 12, 2026 Grant Government grant — STTR: $1.36M (annual award, as published), announced May 12, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Apr 1, 2025 Grant Government grant — STTR: $601,044 (annual award, as published), announced Apr 1, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Oct 1, 2028 (ESTIMATED) · Phase 1 · Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome · NCT07830563

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

May 12, 2026 Government grant — STTR: $1.36M (annual award, as published), announced May 12, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Apr 1, 2025 Government grant — STTR: $601,044 (annual award, as published), announced Apr 1, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07830563	Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome	Phase 1	Not yet recruiting	Oct 1, 2026	Oct 1, 2028 (estimated)